Daré Bioscience, Inc. (NASDAQ:DARE – Get Rating) – Brookline Capital Management issued their Q3 2023 earnings estimates for Daré Bioscience in a report released on Monday, June 5th. Brookline Capital Management analyst K. Dolliver expects that the biotechnology company will earn ($0.07) per share for the quarter. Brookline Capital Management currently has a “Buy” rating […]
Daré Bioscience, Inc. (NASDAQ:DARE) to Post Q2 2023 Earnings of ($0.07) Per Share, Brookline Capital Management Forecasts modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Dare Bioscience (DARE) Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Daré Bioscience (NASDAQ:DARE – Get Rating) and Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Analyst Recommendations This is a breakdown of recent recommendations and […]
Daré Bioscience, Inc. (NASDAQ:DARE – Get Rating) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 378,600 shares, a decrease of 25.9% from the April 30th total of 511,000 shares. Based on an average daily volume of 191,300 shares, the […]